Matches in Wikidata for { <http://www.wikidata.org/entity/Q57243023> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- Q57243023 description "article scientifique publié en 2013" @default.
- Q57243023 description "article" @default.
- Q57243023 description "im Januar 2013 veröffentlichter wissenschaftlicher Artikel" @default.
- Q57243023 description "wetenschappelijk artikel" @default.
- Q57243023 description "наукова стаття, опублікована в січні 2013" @default.
- Q57243023 description "հոդված" @default.
- Q57243023 name "The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of c" @default.
- Q57243023 name "The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of c" @default.
- Q57243023 type Item @default.
- Q57243023 label "The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of c" @default.
- Q57243023 label "The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of c" @default.
- Q57243023 prefLabel "The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of c" @default.
- Q57243023 prefLabel "The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of c" @default.
- Q57243023 P1433 Q57243023-CC95B0BE-266B-4B56-B728-58C3DBBD752D @default.
- Q57243023 P1476 Q57243023-87864124-9FA3-4C37-87A3-C37001177A71 @default.
- Q57243023 P2093 Q57243023-26F577D9-0386-462B-972F-8E87F71BB314 @default.
- Q57243023 P2093 Q57243023-3353AD88-AD7B-49FC-821C-76B0B10C0738 @default.
- Q57243023 P2093 Q57243023-4DF13AC1-F376-4440-8E71-3123301680D7 @default.
- Q57243023 P2093 Q57243023-5C9F9454-9451-451A-8306-4E781E411EDC @default.
- Q57243023 P2093 Q57243023-713DBC63-8CA7-4D5E-837D-A8710C3F41DA @default.
- Q57243023 P2093 Q57243023-7E00D5DB-9625-4468-8D73-88AEE3607873 @default.
- Q57243023 P2093 Q57243023-A304493B-6F64-4669-A8BE-BFA0AA49CAC6 @default.
- Q57243023 P2093 Q57243023-C83F58D3-E072-4C80-87B0-B72D189CC7B1 @default.
- Q57243023 P275 Q57243023-3b459380-2df9-480e-aa3b-6994719076bb @default.
- Q57243023 P2888 Q57243023-4C8D3956-5C5B-4476-82A6-9553649D2233 @default.
- Q57243023 P304 Q57243023-F57D137B-D1D7-422D-92B6-136DF0DED833 @default.
- Q57243023 P31 Q57243023-12CA2827-5CCD-42E4-A3CA-A1A2D9EA71C2 @default.
- Q57243023 P356 Q57243023-EE831E65-FA10-4239-9ED4-BFD3D1957008 @default.
- Q57243023 P433 Q57243023-1DE2D3C9-E6CE-4738-9A58-7EBF14C281B1 @default.
- Q57243023 P478 Q57243023-83A22BAF-B003-48B0-B119-F9AA07200FC1 @default.
- Q57243023 P50 Q57243023-17D72147-FB58-458A-889E-C435F3AFF497 @default.
- Q57243023 P50 Q57243023-E41933CF-674B-4944-9233-06DF557B58D2 @default.
- Q57243023 P577 Q57243023-13321244-6327-46BD-9CA3-DEADD94F340C @default.
- Q57243023 P6179 Q57243023-1E2FA85B-ED98-48AE-BD3C-7C5A426734FB @default.
- Q57243023 P6216 Q57243023-ff03ab43-e8cc-47d8-b436-1da82c97bbcc @default.
- Q57243023 P932 Q57243023-A54CF9CE-69B6-4158-BD1F-C84822A7D11D @default.
- Q57243023 P356 1532-429X-15-S1-O94 @default.
- Q57243023 P1433 Q2180228 @default.
- Q57243023 P1476 "The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity" @default.
- Q57243023 P2093 "Alison Jones" @default.
- Q57243023 P2093 "Gillian Smith" @default.
- Q57243023 P2093 "Jackie Cooper" @default.
- Q57243023 P2093 "Julie Sanders" @default.
- Q57243023 P2093 "Louise Ma" @default.
- Q57243023 P2093 "Michael (Monty) G Mythen" @default.
- Q57243023 P2093 "Michael Thomas" @default.
- Q57243023 P2093 "Paul Kotwinski" @default.
- Q57243023 P275 Q19125117 @default.
- Q57243023 P2888 1532-429x-15-s1-o94 @default.
- Q57243023 P304 "O94-O94" @default.
- Q57243023 P31 Q13442814 @default.
- Q57243023 P356 "10.1186/1532-429X-15-S1-O94" @default.
- Q57243023 P433 "Suppl 1" @default.
- Q57243023 P478 "15" @default.
- Q57243023 P50 Q42778112 @default.
- Q57243023 P50 Q44242090 @default.
- Q57243023 P577 "2013-01-01T00:00:00Z" @default.
- Q57243023 P6179 "1083681707" @default.
- Q57243023 P6216 Q50423863 @default.
- Q57243023 P932 "3559572" @default.